

2024 Current Fiscal Year Report: Medical Imaging Drugs Advisory Committee

Report Run Date: 04/20/2024 10:25:25 AM

1. Department or Agency

Department of Health and Human
Services

2. Fiscal Year

2024

3. Committee or Subcommittee

Medical Imaging Drugs Advisory
Committee

3b. GSA Committee No.

917

4. Is this New During Fiscal Year?

5. Current Charter	6. Expected Renewal Date	7. Expected Term Date
--------------------	--------------------------	-----------------------

No 05/18/2023 05/18/2025

8a. Was Terminated During Fiscal Year?

No

8b. Specific Termination Authority

8c. Actual Term Date

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

Not Applicable

10b. Legislation Pending?

Not Applicable

11. Establishment Authority

Authorized by Law

12. Specific Establishment Authority

21 U.S.C. 394

13. Effective Date

11/28/1990

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Scientific Technical Program
Advisory Board

16a. Total Number of Reports

No Reports for
this Fiscal Year

17a. 0 17b. Closed 0 17c. Partially Closed 0 Other Activities 0 17d. Total 0

Open

Meetings and Dates

No Meetings

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$0.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$0.00	\$0.00
18d. Total	\$0.00	\$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology and makes appropriate recommendations to the Commissioner of Food and Drugs.

20b. How does the Committee balance its membership?

Members are authorities in the fields of nuclear

medicine, radiology, epidemiology or statistics, and related specialties. The committee includes one technically qualified voting member who is identified with consumer interests. The Committee may include one non-voting member who is identified with industry interests.

20c. How frequent and relevant are the Committee Meetings?

The Committee met once in FY-23. On August 1, 2023, the Medical Imaging Drugs Advisory Committee discussed dosimetry data needed to support the initial clinical study in an original investigational new drug (IND) application for certain new positron emission tomography (PET) drugs. FDA obtained the committee's input on the following: (1) the sufficiency of available data from animal or human studies involving certain positron emitting radionuclides (e.g., C11, F18) to allow a reasonable calculation of radiation-absorbed dose to the whole body and critical organs upon administration of a new PET drug containing certain radionuclides to a human subject in first-in-human studies; and (2) the reasonableness of a proposed list of numerical radioactivity thresholds for new PET drugs containing these radionuclides, such that Phase 1 studies that will both (a) administer sub-threshold activities and (b) obtain sufficient human data for dosimetry calculations may be found safe-to-proceed in the absence of dosimetry data based on prior animal administration of the new PET drug under investigation. Agency Action: The Agency is still reviewing the recommendations made at this meeting. It is expected that the Committee will meet one to two times during FY-24.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

Members of the Committee are drawn from academia, research and/or clinical practice. Their advice and input lends credibility to FDA regulatory decisions. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientist on a full-time basis at a maximum rate of compensation.

20e. Why is it necessary to close and/or partially closed committee meetings?

The Committee held no closed meetings during FY-23.

21. Remarks

David Andrews resigned as a MIDAC committee member on January 24, 2022.

Designated Federal Officer

Yvette Waples Designated Federal Officer

Committee Members	Start	End	Occupation	Member Designation
Bolch, Wesley	09/28/2016	06/30/2024	Director, Advanced Laboratory for Radiation Dosimetry Studies, University of Florida	Special Government Employee (SGE) Member
Hackney, David	09/28/2016	06/30/2024	Chief of Neuroradiology, Beth Israel Deaconess Medical Center	Special Government Employee (SGE) Member
Herscovitch, Peter	07/30/2015	06/30/2025	Department Director, PET Department, National Institutes of Health	Regular Government Employee (RGE) Member
Jacobs, Paula	09/28/2016	06/30/2024	Expert Advisor, Division of Cancer Treatment and Diagnosis, National Cancer Institute	Regular Government Employee (RGE) Member
Mintun, Mark	11/01/2019	10/31/2023	Vice President of Pain and Neurodegeneration, Research and Development, Avid Radiopharmaceuticals	Representative Member

Oates, Mary Elizabeth	07/01/2020	06/30/2024	Professor of Radiology and Medicine, University of Kentucky	Special Government Employee (SGE) Member
Rosenthal, Eben	07/01/2021	06/30/2025	Professor and Chair, Department of Otolaryngology, Vanderbilt University Medical Center	Special Government Employee (SGE) Member
Sanghani, Rupa	07/01/2021	06/30/2025	Director of Nuclear Cardiology, Rush University Medical Center	Special Government Employee (SGE) Member

Number of Committee Members Listed: 8

Narrative Description

FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Medical Imaging Drugs Advisory Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology and makes appropriate recommendations to the Commissioner of Food and Drugs. This supports the development of safe and effective new medical technologies, and advances the status of the Agency as a science-based and science-led regulatory agency, providing global leadership in the protection of public health.

What are the most significant program outcomes associated with this committee?

Checked if
Applies

Improvements to health or safety



Trust in government	<input checked="" type="checkbox"/>
Major policy changes	<input checked="" type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input checked="" type="checkbox"/>
Implementation of laws or regulatory requirements	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

Outcome Comments

N/A

What are the cost savings associated with this committee?

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

The utilization of the Medical Imaging Drugs Advisory Committee enabled the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the Committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

5

Number of Recommendations Comments

The Committee made 5 recommendations from FY-03 through the FY-23.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

84%

% of Recommendations Fully Implemented Comments

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, therefore, the Agency has the option of not implementing the advice. This number represents an approximation of the percentage of recommendations that the agency has fully implemented or plans to fully implement.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

10%

% of Recommendations Partially Implemented Comments

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

Product approval issues are first released to the sponsor. When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented. Please see <https://www.fda.gov/>.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input checked="" type="checkbox"/>
Proposed legislation	<input type="checkbox"/>

Approved grants or other payments

☐

Other

☒

Action Comments

FDA approves or chooses not to approve a new medical product.

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

N/A

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO

☒

Online Agency Web Site

☒

Online Committee Web Site

☒

Online GSA FACA Web Site

☒

Publications

☒

Other

☐

Access Comments

NA